Muñoz-Terol José Manuel, Rocha José L, Castro-de la Nuez Pablo, Egea-Guerrero Juan José, Gil-Sacaluga Luis, García-Cabrera Emilio, Vilches-Arenas Angel
Department of Nephrology, Hospital Universitario Virgen del Rocío, 41013 Seville, Spain.
Department of Medicine, University of Seville, 41009 Seville, Spain.
J Pers Med. 2023 Mar 30;13(4):605. doi: 10.3390/jpm13040605.
Survival in patients with end-stage kidney disease (ESKD) on renal replacement therapy (RRT) is less than that of the general population of the same age, and depends on patient factors, the medical care received, and the type of RRT used. The objective of this study is to analyze the factors associated with survival in patients undergoing RRT.
We conducted a retrospective observational study of adult patients with an incident of ESKD on RRT in Andalusia from 1 January 2008 to 31 December 2018. Patient characteristics, nephrological care received, and survival from the beginning of RRT were evaluated. A survival model for the patient was developed according to the variables studied.
A total of 11,551 patients were included. Median survival was 6.8 years (95% CI (6.6; 7.0)). After starting RRT, survival at one year and five years was 88.7% (95% CI (88.1; 89.3)) and 59.4% (95% CI (58.4; 60.4)), respectively. Age, initial comorbidity, diabetic nephropathy, and a venous catheter were independent risk factors. However, non-urgent initiation of RRT and follow-up in consultations for more than six months had a protective effect. It was identified that renal transplantation (RT) was the most influential independent factor in patient survival, with a risk ratio of 0.13 (95% CI (0.11; 0.14)).
The receiving of a kidney transplant was the most beneficial modifiable factor in the survival of incident patients on RRT. We consider that the mortality of the renal replacement treatment should be adjusted, taking into account both modifiable and nonmodifiable factors to achieve a more precise and comparable interpretation.
接受肾脏替代治疗(RRT)的终末期肾病(ESKD)患者的生存率低于同年龄的普通人群,且取决于患者因素、所接受的医疗护理以及所使用的RRT类型。本研究的目的是分析接受RRT患者的生存相关因素。
我们对2008年1月1日至2018年12月31日在安达卢西亚接受RRT的初发ESKD成年患者进行了一项回顾性观察研究。评估了患者特征、所接受的肾病护理以及从RRT开始后的生存情况。根据所研究的变量建立了患者生存模型。
共纳入11551例患者。中位生存期为6.8年(95%CI(6.6;7.0))。开始RRT后,1年和5年生存率分别为88.7%(95%CI(88.1;89.3))和59.4%(95%CI(58.4;60.4))。年龄、初始合并症、糖尿病肾病和静脉导管是独立危险因素。然而,RRT的非紧急启动以及超过6个月的门诊随访具有保护作用。确定肾移植(RT)是患者生存中最具影响力的独立因素,风险比为0.13(95%CI(0.11;0.14))。
接受肾移植是初发接受RRT患者生存中最有益的可改变因素。我们认为,应调整肾脏替代治疗的死亡率,同时考虑可改变和不可改变因素,以实现更精确和可比的解释。